BiOptic, an emerging biotech stock listed on the Emerging Stock Board, held a board meeting on the 24th to approve its 2024 financial report and earnings distribution plan. The company reported a consolidated revenue of NT$202 million for last year, down 11% year-over-year, and a net income after tax of NT$22.73 million, representing a 40% annual decrease. Earnings per share (EPS) stood at NT$0.76. Taking into account the company's steady business development and growth stage, the board resolved to distribute a surplus dividend of NT$1.3 per share, including a cash dividend of NT$0.3 and a stock dividend of NT$1.
Based on BiOptic’s reference price of NT$44 on the Emerging Stock Board on the 24th, the cash dividend yield stands at 0.6%. Of the NT$1.3 dividend, NT$0.7 of the stock dividend will be distributed from capital reserves, which is exempt from individual income tax for shareholders.
Chairman Tsai, Shou-Kuan stated that Mainland China remains BiOptic’s primary sales market. Last year, the region experienced economic imbalance, weakening domestic consumption and investment sentiment, compounded by financial strain on local governments. As a result, China was the only region in the company’s global operations to experience a downturn, dragging overall performance. Nevertheless, BiOptic remained one of the few profitable companies among its peers.
In the first quarter of this year, order momentum in Mainland China saw a notable rebound. Combined with stable growth in other markets, the company posted consolidated revenue of NT$18.01 million in March, up 25.9% month-over-month and 16.85% year-over-year. This helped push first-quarter consolidated revenue to NT$50.91 million, setting a new record high for the same period and marking a 22.9% increase from the previous year.
Tsai noted that domestic demand in China has shown signs of recovery this year, supported by favorable policies, with the overall economy gradually rebounding. Following the inclusion of Illumina, a global leader in gene sequencing, on China’s “unreliable entities list,” BiOptic is expected to benefit from redirected orders. The company is also actively engaging in strategic upstream and downstream partnerships with local firms to build a resilient global supply chain—efforts that are anticipated to further boost performance and market share.
Looking ahead, Tsai believes that the escalating U.S.-China trade tensions may benefit BiOptic by encouraging markets affected by U.S. tariffs to adopt its proprietary brand. The company will also continue its overseas expansion. In addition to its success in European and Middle Eastern markets, BiOptic recently signed a tripartite memorandum of understanding with Her-Mou Electric and Syncore Biotechnology to jointly explore Japan’s precision medicine and wellness market, deepening its presence and effectively diversifying operational risks.
Furthermore, BiOptic has completed internal integration within the group, reducing hidden costs and significantly improving operational efficiency, thereby expanding profitability. With coordinated efforts both internally and externally, the company holds an optimistic outlook for its full-year performance.
Resource: 光鼎生技超額發1.3元股利
